Injection of Bone Marrow Aspirate for Glenohumeral Joint Osteoarthritis: A Pilot Randomized Control Trial
Tim Dwyer, Graeme Hoit, Adrienne Lee, Elyse Watkins, Patrick Henry, Tim Leroux, Christian Veillette, John Theodoropoulos, Darrell Ogilvie-Harris, and Jaskarndip Chahal
Arthroscopy, Sports Medicine, and Rehabilitation; vol 3, iss 5, E1431-E1440, Oct 2021. | doi: 10.1016/j.asmr.2021.07.005
New Encouraging Study:
Comparing the efficacy of a single, intra-articular, non-concentrated bone marrow aspirate (BMA, Marrow Cellution) injection in comparison to Cortisone for the treatment of Glenohumeral Joint Osteoarthritis (GHJ OA).
n = 25 shoulders (22 patients)
| BMA Group (from Baseline to 12 Months) | Steroid Group (from Baseline to 12 Months) |
|---|---|
| Significant improvement was seen in the WOOS index (P = 0.002), QuickDASH (P < 0.001), EQ-5D-5L pain dimension (P = 0.004). | No significant difference was seen for any outcome. |
No significant difference was demonstrated between changes in the WOOS scores compared between groups (P = 0.07). However, a significant difference in changes in scores was seen in the QuickDASH (P = 0.006) and the EQ-5D-5L pain scores (P = 0.003) and the EQ-5D-5L health scores (P = 0.032) in favor of Marrow Cellution Injection.
Conclusions: The results of this study demonstrate that patients with GHJ OA treated with BMA have superior changes in the QuickDASH and EQ-5D-5L pain and health scores but not in the WOOS outcomes measures at 12 months post injection when compared to patients treated with cortisone. However, because of the limited number of patients as a result of the early termination of the study, larger randomized studies are required to confirm these findings.
Level of Evidence: Level II, randomized controlled trial.
______________________________________________________
The Marrow Cellution™ System is designed to minimize and eliminate the restrictive limitations associated with “point of care” processing systems which employ inefficient traditional aspiration trocar technology and are regulated as drugs “Advanced Therapies Medicinal Products (ATMP)”. Marrow Cellution™ is a minimally invasive bone/cell enriched autograft access and retrieval system, which does not require additional manipulation or processing, it never leaves the sterile field and provides rich autograft without associated morbidity.
Visit our Marrow Cellution product page
